SEC Company Response from Quince Therapeutics, Inc. (QNCX) (CIK 0001662774) (IRLA) — May 6, 2019
Quince Therapeutics, Inc. (QNCX) (CIK 0001662774)
Date: May 6, 2019 · CIK: 0001662774 · Accession: 0001193125-19-138185
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-230853
Letter
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
One Bryant Park
New York, New York 10036
Credit Suisse Securities (USA) LLC
Eleven Madison Avenue
New York, New York 10010
May 6, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Suzanne Hayes
Jeffrey Gabor
Joseph McCann
Re: Cortexyme, Inc. Acceleration Request
Acceleration Request
Requested Date: May 8, 2019
Requested Time: 3:30 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Cortexyme, Inc. (the “Company”) for acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-230853), as amended, requesting effectiveness as of 3:30 p.m., Eastern Time, on May 8, 2019, or at such later time as the Company or its outside counsel, Orrick, Herrington & Sutcliffe LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that between April 29, 2019 through the date hereof we have distributed approximately 1,280 copies of the Company’s preliminary prospectus dated April 29, 2019 to prospective underwriters, dealers, institutional investors and others.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature page follows]
Very truly yours,
MERRILL LYNCH, PIERCE, FENNER & SMITH
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
One Bryant Park
New York, New York 10036
Credit Suisse Securities (USA) LLC
Eleven Madison Avenue
New York, New York 10010
May 6, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Suzanne Hayes
Jeffrey Gabor
Joseph McCann
Re: Cortexyme, Inc. Acceleration Request
Acceleration Request
Requested Date: May 8, 2019
Requested Time: 3:30 p.m. Eastern Time
Ladies
and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the
several underwriters, hereby join in the request of Cortexyme, Inc. (the “Company”) for acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-230853), as amended, requesting effectiveness as of 3:30 p.m., Eastern Time, on May 8, 2019, or at such later time as the Company or its outside counsel, Orrick, Herrington &
Sutcliffe LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to
Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that between April 29, 2019 through the date hereof we have distributed approximately 1,280 copies of the Company’s preliminary prospectus dated
April 29, 2019 to prospective underwriters, dealers, institutional investors and others.
We, the undersigned, as representatives of the several
underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities
Exchange Act of 1934, as amended.
[Signature page follows]
Very truly yours,
MERRILL LYNCH, PIERCE, FENNER & SMITH
INCORPORATED
By:
/s/ Charles Newton
Authorized Signatory
CREDIT SUISSE SECURITIES (USA) LLC
By:
/s/ John Hoffman
Authorized Signatory
[Signature Page to
Underwriters’ Acceleration Request]